NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 ...
NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 ...
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND, Sweden, Dec. 20, 2019 /PRNewswire/ -- NeuroVive...
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND, Sweden, Dec. 20, 2019 /PRNewswire/ -- NeuroVive...
NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm:...
NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm:...
NeuroVive Pharmaceutical AB Interim Report January - September 2019 PR Newswire STOCKHOLM, Nov. 20, 2019 - Continued Progress in KL1333 STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important...
NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire STOCKHOLM, Nov. 20, 2019 STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events...
NeuroVive Pharmaceutical AB Interim Report January - June 2019 PR Newswire STOCKHOLM, Aug. 21, 2019 Focus on genetic mitochondrial diseases STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important...
NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire STOCKHOLM, Aug. 21, 2019 STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 2.65 | 2.65 | 2.65 | 0 | 0 | DE |
4 | 0 | 0 | 2.65 | 2.65 | 2.65 | 37905 | 2.65 | DE |
12 | 0 | 0 | 2.65 | 2.65 | 2.65 | 17938 | 2.65 | DE |
26 | 0 | 0 | 2.65 | 2.65 | 2.65 | 8312 | 2.65 | DE |
52 | 0 | 0 | 2.65 | 2.65 | 2.65 | 4249 | 2.65 | DE |
156 | 0 | 0 | 2.65 | 2.65 | 2.65 | 2577 | 2.65 | DE |
260 | 0 | 0 | 2.65 | 2.65 | 2.65 | 2118 | 2.65 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관